Women and Lung Cancer Research and Preventive Services Act of 2025
SB 1157, the Women and Lung Cancer Research and Preventive Services Act of 2025, directs the Secretary of Health and Human Services to conduct an interagency review of federal programs, activities, and strategic plans related to lung cancer research, prevention, diagnosis, and treatment. The review must be done in consultation with the Secretaries of Defense and Veterans Affairs and is focused on improving outcomes for women and for populations with few known risk factors, as well as increasing lung cancer screening rates among groups recommended by the U.S. Preventive Services Task Force.
The bill requires the review to examine existing research, ongoing federally funded projects, and knowledge gaps; consider new research opportunities; and assess public health strategies and educational needs. It specifically highlights potential work on environmental and genomic factors, biomarker testing, risk assessment, diagnosis, and treatment. Within two years of enactment, HHS must submit a report to relevant House and Senate committees describing findings, any federal program changes already made, recommended additional changes, and any statutory or administrative barriers to implementation.
If enacted, the bill would not directly change clinical coverage rules or create a new grant program, but it would require HHS to evaluate and potentially update federal lung cancer-related research and public health efforts. It would affect federal agencies involved in health research and veterans’ and defense health programs, and it could influence future policy, funding priorities, screening outreach, and research agendas related to lung cancer in women and underserved populations.
The available record suggests generally supportive sentiment, as the bill passed the Senate and there are no recorded committee transcripts or votes showing opposition in the provided materials. Its focus on women’s health, underserved populations, and improved screening aligns with a public health-oriented approach that is typically viewed favorably. The fact that it was passed by the Senate indicates at least some bipartisan or broad chamber support, though the bill was later held at the desk in the provided status information.
No specific points of contention are documented in the provided transcripts or vote history. Potential areas of debate, based on the bill text, could include the scope of the federal review, whether HHS should be required to update strategic plans rather than merely study them, and the emphasis on screening and biomarker testing. Any concerns would likely center on administrative burden, federal research priorities, or the extent to which the bill could lead to future spending or policy changes, but none are explicitly recorded here.